Bli medlem
Bli medlem

Du är här


AbCellera: AbCellera and Merck Sign Novel Therapeutic Antibody Discovery Collaboration

AbCellera's Single Cell Antibody Discovery Technology Unlocks the Power of Natural Immunity
VANCOUVER, British Columbia, Jan. 27, 2016 (GLOBE NEWSWIRE) -- AbCellera, a
biotechnology company specializing in the rapid discovery of monoclonal
antibodies from natural immune cells, today announced a new collaboration
with Merck, known as MSD outside the United States and Canada, through a
subsidiary, to generate antibodies against an undisclosed disease target.

"Our platform has the potential to generate functional antibodies against
extremely difficult targets that have been intractable until now," says Dr.
Carl Hansen, President and CEO of AbCellera. "We're excited to partner with a
global innovator like Merck in the discovery of antibodies to advance their
pipeline of next-generation therapies."

"Merck recognizes the innovative science and synergy of collaboration in
British Columbia. Our company has established several life sciences
collaborations in the province aimed at translating breakthrough science into
products that can bring meaningful improvements to patients' lives,"
explained Chirfi Guindo, President and Managing Director at Merck Canada Inc.
"We are pleased to be working with AbCellera to identify novel antibodies
using their innovative microfluidic discovery technology."

Under the agreement, AbCellera will apply its high-throughput antibody
discovery platform to identify antibodies that specifically modulate target
function. The agreement grants Merck the option to develop antibody
candidates identified through the collaboration for specified therapeutic
applications. Financial terms of the deal were not disclosed.

About AbCellera Biologics Inc.

AbCellera is a privately held biotechnology company that provides enabling
technologies for the discovery and development of monoclonal antibody (mAb)
therapies directly from natural immune cells.

AbCellera's lead technology is a proprietary single cell antibody discovery
platform that provides pharma and biotech partners with the ability to
rapidly identify mAb therapeutic candidates from the natural immune
repertoires of any species, including humans. For more information, please

Kevin Heyries
Telephone: 604.827.4151


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AbCellera via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.